Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Breast Neoplasms 181Colorectal Neoplasms 144Stomach Neoplasms 90Rectal Neoplasms 90Pancreatic Neoplasms 74Neoplasm Metastasis 60Neoplasms 48Colonic Neoplasms 40Esophageal Neoplasms 31Gallbladder Neoplasms 18Biliary Tract Neoplasms 17Bile Duct Neoplasms 17Carcinoma, Hepatocellular 15Triple Negative Breast Neoplasms 13Cholangiocarcinoma 12Adenocarcinoma 12Unspecified Adult Solid Tumor, Protocol Specific 11Parkinson Disease 4, Autosomal Dominant Lewy Body 11Liver Neoplasms 10Breast Neoplasms, Male 10Adenocarcinoma Of Esophagus 10Squamous Cell Carcinoma of Head and Neck 9Head and Neck Neoplasms 9Gastrointestinal Neoplasms 9Carcinoma, Renal Cell 8Carcinoma, Non-Small-Cell Lung 8Brain Neoplasms 7Prostatic Neoplasms 6Ovarian Neoplasms 6Uterine Cervical Neoplasms 5

Interventions

Everolimus 6pasireotide 5Octreotide 5lanreotide 2ganitumab 2cabozantinib 2Bevacizumab 2surufatinib 1nintedanib 1ibrutinib 1gallium Ga 68 dotatate 1fosbretabulin 1epothilone B 1conatumumab 1cixutumumab 1carfilzomib 1azaspirane 1arginyllysine 1aflibercept 1Temozolomide 1TKM-080301 1Sunitinib 1Sorafenib 1Somatostatin 1Random Allocation 1Ramucirumab 1Quality of Life 1Patient Reported Outcome Measures 1Nivolumab 1Molecular Diagnostic Techniques 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Carcinoid Tumor × Capecitabine × Clear all
NCT00869050 2016-07-25

Capecitabine and Temozolomide for Neuroendocrine Cancers

Columbia University

Phase 2 Completed
41 enrolled 9 charts
EndocrineGastrointestinalNET

Carcinoid Tumor, Vipoma, Pancreatic Neoplasms, Pheochromocytoma, Somatostatinoma, Zollinger-Ellison Syndrome, Gastrinoma, Carcinoma, Medullary, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡